Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genetic Signatures Ltd. ( (AU:GSS) ) has shared an announcement.
Genetic Signatures Ltd has announced the details of its 2025 Annual General Meeting, scheduled for November 17, 2025. The meeting will cover the consideration of financial reports, allow shareholder engagement with the company’s management and auditors, and include resolutions for the re-election of directors. This AGM is an opportunity for stakeholders to engage with the company’s strategic direction and governance.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd is a specialist molecular diagnostics company focused on developing and commercializing its proprietary platform technology, 3base®. The company designs and manufactures real-time PCR-based products under the EasyScreen™ brand for detecting infectious diseases. Its target markets include major hospitals and pathology laboratories, with a focus on screening for various infectious pathogens, including antibiotic-resistant bacteria and sexually transmitted infections.
Average Trading Volume: 149,750
Technical Sentiment Signal: Sell
Current Market Cap: A$48.83M
See more insights into GSS stock on TipRanks’ Stock Analysis page.